Allergan builds case for migraine drug ubrogepant as FDA ver...

FDA approves Lilly's new migraine attack drug, rival from Al...

The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.

Blow to Novartis as NICE rejects migraine drug Aimovig again

Lundbeck to acquire Alder, and migraine drug, for $1.95bn

Lundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.

Lilly firms up case for Emgality in migraine market chase

Alder gears up for migraine showdown with eptinezumab filing

Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.